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BenzylidenemalononitrileAbstract Ethyl benzoylacetate (1) reacted with 2-benzylidenemalanonitrile to afford the corre-
sponding pyrane derivative (2). The latter compound reacted with 2-benzylidenemalanonitrile, car-
bon disulﬁde, formamide and benzylidene cyclohexanone, respectively, to afford the corresponding
pyrano derivatives (3–6). Compound 2 reacted with ethyl chloroacetate to give compound (8) which
cyclized to compound (9) in the presence of sodium ethoxide. Treatment of compound (2) with ace-
tic acid in the presence of sulfuric acid afforded compound (7) which converted to compound (10)
when reacted with ethylchloroacetate. Compound (10) reacted with sodium ethoxide to give com-
pound (11). The structure of the newly synthesized compounds has been established on the basis of
their analytical and spectral data.
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The 4H-Pyran nucleus is a fertile source of biologically impor-
tant molecules possessing a wide spectrum of biological and
pharmacological activities, such as antimicrobial (Khafagy
et al., 2002), antiviral (Smith et al., 1998; Martinez and Marco,
1997), mutagenicity (Hiramoto et al., 1997), antiproliferative
(Dell and Smith, 1993), sex pheromone (Bianchi and Tava,
1987), antitumor (Mohr et al., 1975), cancer therapy
(Skommer et al., 2006; Anderson et al., 2005; Wang et al.,2000) and central nervous system activity (Eiden and Denk,
1991). Some of these compounds are widely employed as cos-
metics and pigments and as potential biodegradable agrochem-
icals (Hafez et al., 1987). Therefore, the synthesis of such
compounds has attracted strong interest. In recent years, 4-
functionally substituted 1,3-diarylpyrazole derivatives have re-
ceived considerable attention due to their wide range of useful
biological properties, which include antimicrobial (Damlja-
novic et al., 2009; Damljanovic et al., 2009; Prakash et al.,
2008, 2009; Bekhit et al., 2003, 2008; Bekhit and Abdel-Aziem,
2004; Bekhit and Fahmy, 2000; Chovatia et al., 2007), anti-
inﬂammatory (COX-2 inhibitor and ulcerogenic activity)
(Bekhit et al., 2003, 2008; Bekhit and Abdel-Aziem, 2004;
Bekhit and Fahmy, 2000), antitubercular (Chovatia et al.,
2007), antitumor (Fahmy et al., 2002; Abadi et al., 2003),
antiangiogenesis (Abadi et al., 2003), anti-parasitic (Rathelot
et al., 2002) and antiviral activity (Hashem et al., 2007;
Farghaly and El-Kashef, 2006; Farghaly et al., 2006).
Scheme 2 Plausible mechanistic pathway of the synthesis of
pyran derivatives 2.
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Benzylidenemalononitrile was reacted with ethyl benzoylace-
tate 1 in reﬂuxing ethanol catalyzed by piperidine to afford a
yellow solid of compound 2 (Elnagdi et al., 1987; Al-Matar
et al., 2008) (Scheme 1).
Mass spectrum of this product showed m/e 346.38. The IR
spectrum showed absorption bands at 3410–3326 (NH2), 2196
(CN) and 1680 (C‚O) cm1. 1H NMR spectrum revealed a
broad singlet (NH2) at 7.38. On the basis of these data, the
pyran derivative 2 was assigned to this product.
The mechanism for the formation of the pyran derivatives 2
is outlined in Scheme 2. The reaction occurs via an insituinitial
formation of the benzylidinemalononitrile, containing C‚C
double bond which reacts with ethylbenzoylacetate by Michel
addition, cycloaddition, isomerization, aromatization to af-
ford6-Amino-5-cyano-2-methyl-4-phenyl-4H-pyran-3-carbox-
ylic acid ethyl ester 2.
6-Amino-5-cyano-2,4-diphenyl-4H-pyran-3-carboxylic acid
ethyl ester 2 underwent nucleophilic addition with benzylid-
enemalononitrile in reﬂuxing piperidene to afford Ethyl
5-amino-6-cyano-2,4,7-triphenyl-4H-pyrano [2,3-b] pyridine-
3-carboxylate 3 in a good yield. The structure of 3 was con-
ﬁrmed on the basis of elemental analysis. The IR spectrum
showed absorption bands at 3411 (NH2) and 2198 cm
1
(CN). The formation of 3 is assumed to occur via initial forma-
tion of the Michael addition of the amino group in compound
2 to activate the double bond in benzylidenemalononitrile
followed by intramolecular cyclization, then it loses hydrogen
cyanide to afford compound 3 (Al-Omran et al., 2002;
Al-Omran and El-Khair, 2004; El-Khandeel, 1996) (Scheme 3).
Compound 2 was reacted with carbon disulﬁde in ethanol
in the presence of pyridine to give the cyclized compound 4.
This structure was conﬁrmed by IR which revealed absorption
bands corresponding to the 2NH and C‚S functions and also
compound 2 was cyclized to give the corresponding Ethyl 4-
amino-5,7-diphenyl-5H-pyrano [2,3-d] pyrimidine-6-carboxyl-
ate 5 on treatment with formamide.
Compound 2 was reacted with (E)-2-benzylidenecyclohexa-
none in the presence of piperidine to afford the corresponding
Ethyl 5-amino-9-benzylidene-2,4-diphenyl-6,7,8,9-tetrahydro-
4H-pyrano [2,3-b] quinoline-3-carboxylate 6.
Ring transformation of 2 by sulfuric acid in the presence of
acetic acid under analogous reaction conditions regioselec-
tively provided Ethyl 5-cyano-6-hydroxy-2,4-diphenyl-1,4-
dihydropyridine-3-carboxylate 7 in good yields.
The cyclocondensation of compounds 2 and 7 with ethyl
chloroacetate was performed in N,N-dimethylformamide in
the presence of catalytic amount of potassium carbonate and
to give the corresponding compounds 8 and 10 respectively,
which were readily cyclized to the corresponding pyran deriv-Scheme 1 Synthesis pathway for tatives 9 and 11 respectively Schemes 4 and 5. Similarly, all
these compounds were characterized on the basis of spectral
studies. All spectroscopic data have been given in experimental
section. All the compounds were screened for their antibacte-
rial and antifungal activities.
3. Antimicrobial activity
The activity of the synthesized products was tested by the disk
diffusion method. The cup-plate technique was used for the
determination of these antimicrobial effects. Antibacterial
and antifungal assays using a method Whatman No. 4 ﬁlter pa-
per discs (0.5 cm diameter) were soaked in the tested sample.
The samples of compounds were dissolved in DMSO. 0.24 lg
of each sample was dissolved in 0.1 ml DMSO, then 0.1 ml of
each sample was used with some gram positive bacteria such
as (Sarcina lutea, Staphylococcusaureus and Bacillus subtilis),
gram negative bacteria such as (Pseudomonas aeuroginosa,
Escherichia coli, Agrobacterium and Erwinia sp.) and fungal
(Aspergillus niger, Penicilliumfuniculosum) under aseptic condi-
tions. The medium for cultivation of test organisms was nutri-
ent agar, and the petri-dishes were incubated at 30 C for 24 h.
The results were recoded by measuring the inhibition zones
caused by various compounds on the microorganisms. Activity
of each compound was compared with ciproﬂoxacin and sul-
fametoxazol as standards (Davis et al., 1996; Raman et al.,
2001). These results are summarized in Table 1. From the re-
sults obtained, it is obvious that most of the tested compounds
posses slight or no activity at all toward the tested microorgan-
isms. However, some compounds showed considerable activity
against the tested bacteria like 7, 9 and 11. Others exhibit mod-
erate or slight activity against fungi such as 2 and 3.
4. Experimental section
All melting points were determined on an electrothermal appa-
ratus and are uncorrected. IR spectra were recorded (KBrhe preparation of compound 2.
Scheme 3 Synthetic pathway for the preparation of compounds 3–7.
Scheme 4 Synthetic pathway for the preparation of compounds 8 and 9.
Scheme 5 Synthetic pathway for the preparation of compounds 10 and 11.
S968 W.S. Shehab, A.A. Ghoneimdiscs) on a Shimadzu FT-iR 8201 PC spectrophotometer. 1H
NMR spectra were recorded in DMSO on a Varian Gemini
300 MHz spectrometer and chemical shifts are expressed in
8 units using TMS as an internal reference, mass spectra were
recorded on a GC–MS QPIOOO EX Shimadzu. Elemental
analyses were carried out at the Micro analytical Center of
the Cairo University.4.1. 6-Amino-5-cyano-2,4-diphenyl-4H-pyran-3-
ethylcarboxylate (2)
A mixture of benzylidene malononitrile (1.54 g, 0.1 mol) with
ethyl benzoylacetate 1 (1.39 g, 0.1 mol) in the presence of
piperidine was reﬂuxed for 4 h. The solid product, so formed,
was ﬁltered of and recrystallized from ethanol. This compound
Table 1 Antimicrobial activity of the compounds considered.
Compound Microorganisms\\
1 2 3 4 5
2 + + +  
3 + +   
7 +++  + + ++
9  ++ + + 
11 +++ + + + ++
Sulfametoxazol +++ + ++ ++ +++
Ciproﬂoxacin +++ ++ +++ + +++
The solvent is dimethylsulphoxide (DMSO).
\\1: Stphylococcus aureus. 2: Pseudomonas aeuroginosa. 3: Bacillus
subtilis. 4: Aspergillus niger. 5: Penicillium funiculosum.
+++: Highly active. ++: Moderately active. +: Slightly active.
: Inactive
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IR (KBr): 1680 (C‚O), 2196 (CN), 3326, 3410 (NH2) cm
1,
1H NMR (DMSO-d6): d 0.76 (t, 3H, ester CH3), 3.77 (q, 2H,
CH2), 7.38 (s, 2H, NH2), 7.25–7.42 (m, 10H, Phenyl). Analysis
calculated for (C21H18N2O3; 346.38) C, 72.82; H, 5.24; N, 8.09.
Found; C, 72.63; H, 5.02; N, 7.98.
4.2. Ethyl 5-amino-6-cyano-2,4,7-triphenyl-4H-pyrano [2,3-b]
pyridine-3-carboxylate (3)
A mixture of 2 (3.48 g, 10 mmol) and 2-benzylidenemalononit-
rile (1.54 g, 10 mmol) in piperidine (20 mL) was reﬂuxed for
4 h. The reaction mixture was then allowed to cool at room
temperature. The solid product so formed was collected by ﬁl-
tration and recrystallized from ethanol as pale yellow crystals,
3.11 g (71%), mp. 188–190 C; IR (KBr): 3411–3290 (NH2),
2198 (CN), 1679 (C‚O) cm1; 1H NMR (DMSO-d6): d 0.97
(t, 3H, CH3), 3.56 (q, 2H, CH2), 7.20–8.14 (m, 15H, Ar-H),
8.20 (brs, 2H, NH2). Analysis calculated for C30H23N3O3
(473.52) C, 76.09; H, 4.90; N, 8.87. Found: C, 76.19; H 4.65;
N, 8.65.
4.3. Ethyl 4-imino-5,7-diphenyl-2-thioxo-1,2,4,5-
tetrahydropyrano [2,3-d] [1,3] thiazine-6-carboxylate (4)
A mixture of 2 (10 mmol) in dry pyridine (15 ml) and CS2
(0.76 g, 10 mmol) was reﬂuxed on a water bath for 9 h. The
reaction mixture was poured into cooled water and neutralized
with dil. HCl. The solid product was collected by ﬁltration,
washed with water dried and crystallized from benzene to af-
ford (73% of 4); m.p. 232–236 C. IR (KBr):3318 (NH),
1578 (C‚N), 1280 (C‚S), 1722 (C‚O) cm1; 1H NMR
(DMSO-d6): d 0.983 (t, 3H, ester CH3), 3.98 (q, 2H, CH2),
3.37 (s, 1H, 4-H), 6.95 (brs, NH, exchangeable), 7.15–7.32
(m, 10H, Phenyl), 9.08 (brs, NH, exchangeable). Analysis cal-
culated for C22H20N2O3S2 (422.52) C, 62.54; H, 4.29; N, 6.63;
S, 15.18. Found. C, 62.35; H, 4.73; N, 6.62; S, 15.08.
4.4. Ethyl 4-amino-5,7-diphenyl-5H-pyrano [2,3-d] pyrimidine-
6-carboxylate (5)
A mixture of compound 2 in dry ethanol and formamide
(10 ml) was reﬂuxed for 4 h. The precipitate was collected byﬁltration and recrystallized from ethanol to give 5. Yield
65%; IR (KBr): 3411–3326 (NH2), 1610 (C‚N), 1678
(C‚O) cm1; 1H NMR (DMSO-d6): d: 1.03 (t, 3H, ester
CH3), 3.98 (q, 2H, CH2), 3.36 (s, 1H, 4-H), 7.05 (s, 2H,
NH2), 7.05–7.32 (m, 10H, Phenyl). Analysis calculated for
C22H19N3O3 (373.4); C, 70.76; H, 5.13; N, 11.25. Found: C,
70.73; H, 5.02; N, 11.03.
4.5. Ethyl 5-amino-9-benzylidene-2,4-diphenyl-6,7,8,9-
tetrahydro-4H-pyrano [2,3-b] quinoline-3-carboxylate (6)
A mixture of (E)-2-benzylidenecyclohexanone (1.54 g, 0.1 mol)
with compound 2 (0.1 mol) in 50 ml ethanol in the presence of
piperidene was reﬂuxed for 3 h. The solid product, so formed,
was ﬁltered off and recrystallized from ethanol to give 87%
yield; m.p. 234–231 C. IR (KBr): 3429–3336 (NH2), 1618
(CN), 1543 (C‚C) cm1; 1H NMR (DMSO-d6): d 0.96 (t,
3H, ester CH3), 1.96 (s, 6H, 3CH2), 2.98 (q, 2H, CH2), 4.35
(s, 1H, 4-H), 6.83 (s, 2H, NH2), 7.25–7.32 (m, 10H, Phenyl).
Analysis calculated for C34H30N2O3 (514.61); C, 79.35; H,
5.88; N, 5.44. Found: C, 79.39; H, 6.09; N, 5.47.
4.6. Ethyl 5-cyano-6-hydroxy-2,4-diphenyl-1,4-dihydropyridine-
3-carboxylate (7)
To a solution of pyran 2 (0.1 mol) in 30 ml glacial acetic acid
was added 1 ml of concentrated sulfuric acid and the mixture
was reﬂuxed for 1 h, then left to cool. The precipitated solid
was ﬁltered off and recrystallized to afford (85% of 7) m.p.
296–298 C IR (KBr): 3326–3425 (OH, NH), 2200 (CN),
1705 (C‚O) cm1; 1H NMR (DMSO-d6): d 0.93 (t, 3H, ester
CH3), 3.98 (q, 2H, CH2), 4.39 (s, 1H, 4-H), 6.95 (s, H, NH),
7.15–7.32 (m, 10H, Phenyl), 11.24 (s,1H, OH). Analysis calcu-
lated for (C21H18N2O3 (346.38) C, 72.82; H, 5.24; N, 8.09.
Found: C, 72.80; H, 5.11; N, 8.13.
4.7. Ethyl 5-cyano-6-(2-ethoxy-2-oxoethylamino)-2,4-diphenyl-
4H-pyran-3-carboxylate (8)
A solution of 2 (0.1 mol) in 250 ml dry N,N-dimethylformam-
ide was heated at 80–85 C with ethyl chloroacetate (0.11 mol)
in an oil bath in the presence of anhydrous potassium carbon-
ate (0.11 mol). The reaction mixture was cooled and poured
onto ice water A pale yellow crystalline solid was separated ﬁl-
tered, washed thoroughly ﬁrst with cold water and then with
cold ethanol, recrystallized from 95% ethanol, yield 70%
m.p. 220–222 C IR (KBr): 3120 (NH), 2197 (CN), 1713 (2
CO) cm1; 1H NMR (DMSO-d6): d1.03 (2t, 6H, ester
2COOCH3), 3.98 (2q, 4H, 2CH2), 3.30 (s, 1H, 4-H), 2.17 (s,
2H,CH2), 6.75 (s, 1H, NH), 7.21–7.32 (m, 10H, Phenyl). Anal-
ysis calculated for C25H24N2O5 (432.47) C, 69.43; H, 5.59; N,
6.48. Found: C, 69.49; H, 5.56; N, 6.44.
4.8. Diethyl 5-amino-2,4-diphenyl-4,7-dihydropyrano [2,3-b]
pyrrole-3,6-dicarboxylate (9)
A sample of compound 8 (0.01 mol) in sodium methoxide
(0.23 Na/30 mL methanol) was heated under reﬂux for 2 h,
and then allowed to cool. The solid product was collected by
ﬁltration, washed with water, and recrystallized to give 9; yield
S970 W.S. Shehab, A.A. Ghoneim67%; m.p. 297–299 C IR (KBr): 3330 (NH2). 1706 (C‚O);
1H NMR (CDCl3) d 0.63 (s, 6H, 2CH3), 2.28 (s, 1H, H-4),
3.65 (q, 2H, CH2), 5.78 (s, 1H, NH), 6.86 (brs, 2H, NH2),
7.14–7.26 (m, 10H, phenyl); Analysis calculated for
C26H27N2O5 (447.5): C, 69.78; H, 6.08; N, 6.26. Found: C,
69.73; H, 6.17; N, 6.01.
4.9. Ethyl 5-cyano-6-(2-ethoxy-2-oxoethoxy)-2,4-diphenyl-1,4-
dihydropyridine-3-carboxylate (10)
This was prepared by the same conditions used for the above
prepared compound. The product was crystallized from etha-
nol to give 10. IR (KBr): 3326 (NH), 1708 (2 CO) cm1; 1H
NMR (DMSO-d6): d 0.93 (2 t, 6H, ester 2CH3), 3.78 (2 q,
4H, 2CH2), 4.21 (s, 1H, 4-H), 6.91 (s, 1H, NH), 7.15–7.32
(m, 10H, Phenyl). Analysis calculated for (C25H24N2O5:
432.47) C, 69.43; H, 5.59; N, 6.48. Found: C, 69.37; H, 6.09;
N, 6.50.
4.10. Diethyl 3-amino-4,6-diphenyl-4,7-dihydrofuro [2,3-b]
pyridine-2,5-dicarboxylate (11)
This was prepared by the same conditions used for the above
prepared compound 9. The product was crystallized from eth-
anol to give (76% of 11); m.p. 278–280. IR (KBr): 3411–3326
(NH2), 1718 (CO) cm
1; 1H NMR (DMSO-d6): d 0.73 (2t, 6H,
ester 2CH3), 3.88 (2q, 4H, 2CH2), 3.64 (s, 1H, 4-H), 5.76 (s,
1H, NH), 6.95 (s, 2H, NH2), 7.15–7.32 (m, 10H, Phenyl). Anal-
ysis calculated for C26H27N2O5 (447.5) C, 69.78; H, 6.08; N,
6.26. Found: C, 69.76; H, 6.09; N, 6.29.
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